Insights from global data for use of rotavirus vaccines in India

T. S. Rao, Rashmi Arora, Ajay Khera, Jacqueline E. Tate, Umesh Parashar, Gagandeep Kang, M. K. Bhan, Ashish Bavdekar, Temsunaro R. Chandola, Nita Bhandari, Sunita Taneja, Tivendra Kumar, Vinohar Balraj, Jayaprakash Muliyil, Jacob John, Mohan V. Raghava, Rajiv Sarkar, Umesh D. Parashar, Nicholas C. Grassly, Mathuram Santosham

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


Rotavirus vaccines are being introduced in several low- and middle-income countries across the world with and without support from the GAVI Alliance. India has the highest disease burden of rotavirus based on morbidity and mortality estimates and several indigenous vaccine manufacturers are developing rotavirus vaccines. One candidate has undergone phase III testing and others have completed evaluation in phase II. Global data on licensed vaccine performance in terms of impact on disease, strain diversity, safety and cost-effectiveness has been reviewed to provide a framework for decision making in India.

Original languageEnglish (US)
Pages (from-to)A171-A178
Issue numberS1
StatePublished - 2014

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases


Dive into the research topics of 'Insights from global data for use of rotavirus vaccines in India'. Together they form a unique fingerprint.

Cite this